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Abstract
Atrial fibrillation (AF) frequently coexists in the setting of myocardial infarction (MI), being 
associated with increased mortality. Nonetheless, temporal trends in the occurrence of AF 
complicating MI and in the prognosis of these patients are not well described. We examined 
temporal trends in prevalence of AF in the setting of MI and the effect of AF on prognosis in the 
community. We studied a population-based sample of 20,049 validated first incident nonfatal 
hospitalized MIs among 35- to 74-year old residents of 4 communities in the ARIC Study from 
1987 through 2009. Prevalence of AF in the setting of MI increased from 11% to 15% during the 
23-year study period. The multivariable adjusted odds ratio for prevalent AF, per 5-year 
increment, was 1.11 (95% confidence interval [CI]: 1.04–1.19). Overall, in patients with MI, AF 
was associated with increased 1-year case fatality (OR 1.47, 95% CI 1.07–2.01) compared to those 
without AF. However, there was no evidence that the impact of AF on MI survival changed over 
time or differed over time by sex, race or MI classification (all p-values > 0.10). In conclusion, co-
occurrence of AF in MI slightly increased between 1987 and 2009. The adverse impact of AF on 
survival in the setting of MI was consistent throughout. In the setting of MI, co-occurrence of AF 
should be viewed as a critical clinical event, and treatment needs unique to this population should 
be explored further.
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Despite the significant decline in the incidence rate of myocardial infarction (MI) since the 
end of the 20th century,1–3 the estimated annual incidence of MI in the US remains high at 
525,000 cases.4 A recent systematic review and meta-analysis reported that approximately 1 
in 10 MI patients had concomitant AF,5 which was associated with a significantly increased 
risk of death.5 However, little is known about the temporal trends related to the association 
of AF with prognosis of MI patients. Two studies reported a significantly higher mortality 
rate among MI patients who developed AF compared to those who did not, with no evidence 
of a clinically meaningful improvement in survival during the study period among those 
with coexisting AF and MI.6,7 Both studies were relatively small and lacked precision in 
trend analyses. Furthermore, the prior studies on prognosis of patients with co-occurring AF 
and MI have been conducted in predominately white communities, which is a limitation 
because the decline in incidence and mortality rates for MI have been slower among blacks 
compared to whites, especially among men,1 and blacks have a lower risk of AF compared 
to whites.8 Our aims were to estimate the prevalence of AF in the setting of MI over time as 
well as by sex, race and MI classification; to describe the impact of AF on mortality; and to 
assess the temporal trends in mortality among MI patients with and without concomitant AF 
overall and among subgroups utilizing a large community-based biracial study.
METHODS
The community surveillance component of the ARIC Study, described previously, was 
designed to provide knowledge about the burden of and trends in CHD morbidity and 
mortality in 4 US communities (details included in supplemental material).9,10
Presence of AF during the MI hospitalization was defined by the presence of AF 
International Classification of Diseases, 9th revision, Clinical Modification, (ICD-9-CM) 
hospital discharge diagnosis codes of 427.3x in any position. Validity of ICD codes for the 
identification of AF has been described elsewhere.11 We did not distinguish between AF 
that started before versus during the MI hospitalization.
All-cause mortality, at 28-days and 1-year, was determined by medical record review, state 
death records linkage, and linkage with the National Death Index. Deaths were classified 
based on the duration from date of hospital admission until date of death.
Patient characteristics, including age, sex, and race were abstracted from medical records by 
trained and certified study staff as were data on cardiovascular-related comorbidities, 
including a history of hypertension, stroke and diabetes. Prescription medications at 
admission, during hospitalization or at discharge and procedures were classified as yes or 
no. New therapies have been introduced during the study period and the impact of these 
therapies was estimated beginning in the year for which complete treatment information was 
available: ACE or angiotensin II inhibitors, 1992; Antiplatelet agents other than aspirin, 
1997; and lipid-lowering agents, 1999.
Bengtson et al. Page 2













Adjustment for disease severity and clinical comorbidities was performed with a modified 
Predicting Risk of Death in Cardiac Disease Tool (PREDICT) score.12 The PREDICT score, 
developed in a community-based study, utilizes information routinely collected during a 
hospitalization with MI, including cardiogenic shock, clinical history (cardiac events and 
procedures), age, severity of ECG changes, congestive HF, kidney function, and the 
Charlson Comorbidity Index, to determine mortality risk. Data on renal function has not 
always been collected in ARIC community surveillance, so a validated modification of the 
PREDICT score, ranging from 0 to 21, was used.13,14
Hospitalized non-fatal first incident definite and probable MIs were eligible for inclusion. 
Patients whose race was not white or black as well as nonwhites from the Minneapolis and 
Washington County field centers were excluded (n = 442) due to insufficient sample size. 
Patients with unknown mortality status at 28-days or 1-year (n = 342) or with incomplete 
covariate data (n = 91) were also excluded.
The temporal trend in prevalence of coexisting AF among MI patients was assessed with a 
logistic regression model using year (continuous) as the main independent variable adjusted 
for age (5-year groups), sex, a composite race and field center variable, number of ICD-9-
CM diagnosis codes, MI classification (STEMI/NSTEMI/Unclassified) and severity 
(PREDICT). The impact of AF on survival overall was assessed with logistic regression 
models adjusted for age, sex, race, field center, MI classification, number of ICD-9-CM 
codes, severity (PREDICT), presentation characteristics (first systolic blood pressure and 
first pulse), medications, and therapeutic procedures, and within subgroups defined by sex, 
race, and MI classification. Trends in the association of AF with 1-year case fatality among 
MI patients were examined with multivariable logistic regression models. Pre-specified 2-
way multiplicative interactions of trends in prevalence and mortality with sex, race, and MI 
classification were examined. A p<0.10 was considered evidence of effect modification.
All analyses weighted the contribution of each hospitalization by the inverse of its sampling 
probability to generate point, variance and 2-tailed P values that account for the sampling 
design. All statistical analyses were performed using survey procedures in SAS (version 9.2; 
SAS Institute, Inc, Cary, NC).
RESULTS
Our final analytic sample included 13,155 definite and probable first incident MIs, for a 
weighted sample of 20,049. Baseline patient characteristics over time, in 4-year intervals, 
are shown in Table 1, while Table 2 shows prevalence of medications and therapeutic 
procedures. The age and sex distributions of the sample were stable over the study period, 
with an overall mean age of 59 years at the time of hospitalization; women accounted for 
36% of the sample. The prevalence of AF accompanying MI increased slightly over the 23-
year study period (Table 1), although this was due primarily to a low prevalence of 
concomitant AF in the first few years. The proportion of MIs classified as NSTEMI 
increased during the study period.
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The prevalence of coexisting AF in the setting of MI increased over the study period. After 
adjustment there was no evidence that the time trend in prevalence of co-occurring AF and 
MI differed by sex (p for interaction = 0.43) or race (p for interaction = 0.69); however, 
there was evidence of a different AF time trend by MI classification (p for interaction = 
0.005) (Figure 1). The prevalence of AF in patients with NSTEMI or unclassified MI 
(neither STEMI nor NSTEMI) increased during the study period, while among STEMI 
patients the prevalence of AF decreased.
Overall, the presence (versus absence) of AF complicating MI was associated with more 
than a 2-fold increased odds of post-MI death at 28-days and 1-year, after adjustment for age 
group, sex, race, field center and year (Table 3). This association did not differ by sex, race 
or MI classification.
Among those with AF and MI, there was no evidence of improved 1-year survival over time 
(Table 4). Conversely, among those without AF, 1-year survival improved over time. There 
was no statistical evidence that the trend in 1-year MI survival differed for those with versus 
without AF (p for interaction = 0.45). The impact of AF on 1-year case fatality did not differ 
by sex, race or MI classification. Within strata defined by AF status as well as sex, race or 
MI classification, respectively, temporal trends in survival were similar; the point estimates 
suggested improved survival among all strata, except men with AF, over the study period. A 
sensitivity analysis, excluding those who had a cardiac operative procedure performed 
during the index hospitalization, was performed and results were consistent with the primary 
analysis.
DISCUSSION
In this population-based sample of validated MI hospitalizations, the prevalence of 
concomitant AF in MI increased slightly from 1987 to 2009 and was approximately 15% in 
the most recent years. The secular trend in the prevalence of AF in the setting of MI differed 
by MI classification; the prevalence of coexisting AF increased over time among NSTEMI 
and unclassified MIs and decreased among STEMIs. Co-occurrence of AF in the setting of 
MI was associated with an increased risk of death and this association did not differ by sex, 
race or MI classification. Finally, improvements over time in 1-year survival among MI 
patients were greater in those without AF compared to those with AF, but this difference 
was not statistically significant.
The percent of patients with co-occurring AF increased over time among those with 
NSTEMI and unclassified MIs, while simultaneously decreasing among STEMIs. It is not 
surprising that AF was more common among NSTEMIs as these patients tend to be older 
and have more comorbidities.15–17 However, we adjusted for age group, sex, race, field 
center, MI classification, severity of MI and number of ICD-9-CM diagnosis codes. This is 
not the first study to report an increasing prevalence of AF complicating NSTEMI; in the 
Worcester Heart Attack Study, the adjusted OR of having AF in the setting of NSTEMI was 
1.96 (95% CI: 1.38 – 2.79) in 2005 compared to 1997, while in STEMI the corresponding 
OR was 1.53 (95% CI: 0.97 – 2.44).2 In addition to the aging population, the prevalence of 
comorbidities, including known risk factors for AF, has increased over time, especially 
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among NSTEMIs, and could be driving the trend of increasing co-occurrence of AF and 
NSTEMI.18 Potential explanations for the difference between STEMI and NSTEMI include 
changes in patient characteristics over the study period, changes in treatment strategies 
resulting in STEMI patients undergoing catheterization and subsequently reducing AF risk, 
or the impact of AF on the ECG ST segments, making it more difficult to classify an event 
as STEMI in the presence of AF.
Regardless of the temporal trends, AF complicating MI is consistently associated with worse 
survival;5–7,19,20 in a meta-analysis of 23 studies that provided multivariable adjusted 
analyses, the pooled mortality OR associated with AF in MI patients was 1.46 (95% CI 1.35 
– 1.58).5 Our results are consistent with previous studies. Given the independent negative 
impact of AF on survival following MI, the occurrence of AF in MI should be viewed as a 
minor event relative to more severe complications like ventricular tachycardia, but should be 
recognized as a critical condition. To date, prognostic risk scores for MI ignore AF in 
determining the risk of death and therapeutic decisions.21,22 Further consideration of AF in 
prognostic scores is warranted, especially because prevalence of AF in the community is 
estimated to increase as the population ages,23,24 and because AF often complicates MI.5,20
Moreover, patients with AF complicating MI have unique treatment needs that are not fully 
understood. Aspirin is a cornerstone of acute MI therapy and dual antiplatelet therapy 
(aspirin and clopidogrel) is considered the gold standard following percutaneous coronary 
intervention.25 However, the combination of oral anti-coagulants and antiplatelets is 
associated with a high frequency of major bleeding.26 Thus, the optimal treatment strategy is 
unclear when the risks of thromboembolism and bleeding are considered. The introduction 
of new direct oral anticoagulant agents for the prevention of thromboembolic complications 
in AF as well as for the treatment of acute coronary syndromes raises additional questions 
about the optimal treatment strategy.27,28
There are several limitations of this study. The diagnosis of AF relied on ICD-9-CM hospital 
discharge codes and is not otherwise adjudicated. Nonetheless, this method has been found 
to have acceptable validity in epidemiologic studies.8,11 Temporal trends in co-occurrence 
of AF and MI are based on the proportion of MIs in a given time with documented AF. It is 
possible that the trends would change if this analysis were based on rates of co-occurrence, 
which would scale the results to account for changes in the size of the population. The onset 
of AF was unknown and we included both AF occurring before and during the MI 
hospitalization. However, in a prior study the occurrence of AF before or after MI was 
associated with an increase in mortality over no AF in MI patients.6 In our study, patients 
who developed AF after hospital discharge were not identified and would be misclassified. 
Nevertheless, there is a positive association between time from incident MI to first-detected 
AF and risk of death;6 consequently, our reported association likely was underestimated. 
Coding practices likely have changed over time. In an effort to account for these changes, 
analyses were adjusted for the number of ICD-9-CM codes. A previous analysis in ARIC 
reported greater declines over time in first myocardial infarction after accounting for trends 
in cardiac biomarker utilization.1 The advent of more sensitive biomarkers has particularly 
impacted the diagnosis of NSTEMI, with less severe cardiac events being classified as 
NSTEMI. However, it is unclear if the net effect would increase or decrease the co-
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occurrence of AF; it is possible that transient increases in cardiac biomarkers associated with 
rapidly conducting AF would result in a small increase in concomitant AF. It is also 
plausible that classification of less severe cardiac events would result in fewer events of co-
occurring AF.
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Refer to Web version on PubMed Central for supplementary material.
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Three-year moving average of AF prevalence in hospitalizations with incident definite or 
probable myocardial infarction overall and by subtypes (ST-Elevation myocardial infarction 
[STEMI], non-ST-Elevation myocardial infarction [NSTEMI], and unclassified) in the 
Community Surveillance component of the Atherosclerosis Risk in Communities Study, 
1987 – 2009
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